Get Plus

Sign in to baba News

One account across the web, iPhone and Android — your subscription follows it.

or use an email code

Search stories

Type at least two characters. Results come from every newsroom baba reads.

↑↓ to move · ↵ to open · esc to close

Sign in to baba News

Sign in to keep asking. News Plus removes the daily limit.

or use an email code

Arutz ShevaHealth

Health Basket Committee Member Reveals Life-or-Death Decision Dilemmas

Translated & summarized from Arutz Sheva by baba

RightCharged tone

Hebrew · 1 newsroom

Rabbi Yosef Tzvi Rimon, a member of Israel's Health Basket Committee, described the difficult decisions involved in funding new medical treatments. The committee faces requests worth 3 billion shekels with a budget of 650 million shekels. He recounted a case where a 240 million shekel treatment for 24 children with Duchenne muscular dystrophy was denied due to insufficient evidence of efficacy. Rimon also highlighted the challenge of choosing between extending the lives of a few or improving the quality of life for many.

The story in 5 lines · by baba

  • Rabbi Yosef Tzvi Rimon detailed the ethical dilemmas of Israel's Health Basket Committee.
  • The committee must choose among new treatments with requests totaling 3 billion shekels against a 650 million shekel budget.
  • A 240 million shekel treatment for Duchenne muscular dystrophy was denied due to insufficient efficacy evidence.
  • Decisions involve comparing extending few lives versus improving many lives.
  • Rabbi Rimon described the personal and halachic weight of these life-and-death choices.

Rabbi Yosef Tzvi Rimon, a four-year member of Israel's Health Basket Committee, has revealed the profound ethical and financial challenges involved in deciding which life-saving treatments to fund. Speaking at a Torah and Science conference, Rabbi Rimon described the agonizing choices faced by the committee, which must allocate a limited budget to a vast number of expensive new medical treatments.

He detailed a particularly harrowing encounter where dozens of parents and children suffering from Duchenne muscular dystrophy, a severe degenerative disease, came to his home seeking approval for a new treatment. The cost for 24 children needing the one-time, 10 million shekel per-injection treatment would have been 240 million shekels, over a third of the committee's entire annual budget of 650 million shekels for new treatments, against new requests totaling 3 billion shekels. The committee ultimately decided against funding the drug, as the medical evidence for its efficacy, particularly long-term, was not sufficiently convincing to justify such an enormous expenditure.

Rabbi Rimon also presented a dilemma comparing funding a brain cancer drug that could grant 95 patients three additional years of life for approximately 72 million shekels, versus an automated diabetes treatment system that could significantly improve the lives of 10,000 patients for a similar cost. He explained that these decisions carry deep halachic (Jewish legal) dimensions, comparing the committee's task to ancient debates about saving one life versus another, but noting the added complexity of allocating public funds for the benefit of the entire population.

He shared the personal toll these decisions take, admitting that after his first committee meetings, he was physically ill from the weight of denying treatments. Over time, however, he learned to focus on the positive impact of the approved treatments, acknowledging that his decisions ultimately enable better medical care for hundreds of thousands of people.

Arutz ShevaRight · Beit El

Sign in to baba News

Sign in to follow newsrooms, topics and people.

or use an email code

HealthTopic

Sign in to baba News

Sign in to follow newsrooms, topics and people.

or use an email code

Mentioned

Open the Wire